This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (19) Citing Articles via Google Scholar Google Scholar Articles by Dietrich, W. Articles by Kriner, M. Search for Related Content PubMed PubMed Citation Articles by Dietrich, W. Articles by Kriner, M. Related Collections Cardiovascular Coagulation Pharmacology

---

CARDIOVASCULAR ANESTHESIA

High-Dose Aprotinin in Cardiac Surgery: Is High-Dose High Enough?

An Analysis of 8281 Cardiac Surgical Patients Treated with Aprotinin

Wulf Dietrich, MD, PhD^*, Raimund Busley, MD^*, and Monika Kriner, MSc

From the *Department of Anesthesiology, German Heart Center Munich; and Institute for Statistics and Epidemiology, Medical Faculty, Technical University, Munich, Germany.

Address correspondence and reprint requests to W. Dietrich, MD, PhD, German Heart Center Munich, Technical University, Munich, Germany. Address e-mail to dietrich{at}dhm.mhn.de.

In this retrospective analysis we tested the hypothesis that aprotinin doses of more than 6 x 10⁶ kallikrein inhibiting units (KIU) per patient may be more effective in reducing bleeding compared with the high-dose regimen of 5–6 x 10⁶ KIU aprotinin. The aprotinin doses administered for 8281 adult cardiac surgical patients were correlated to body weight and time of operation and calculated in KIU per kg body weight and minute of operation. Linear and logistic regression models were designed to detect potential associations between dose and postoperative bleeding, transfusion, and other covariates. The 6-h chest tube drainage in the lowest quartile dosing group was 447 ± 319 mL (mean ± sd) compared with 360 ± 290 mL in the highest quartile dosing group (P < 0.001). The proportion of patients requiring allogeneic blood transfusion was reduced from 55% to 47% comparing the lowest with the highest dosing group (P < 0.01). Aprotinin dose was also an independent predictor for rethoracotomy for surgical hemostasis (1.9% in the highest quartile to 2.4% in the lowest dosing quartile; P < 0.01). The risk of renal failure requiring dialysis (2.3% in the highest dosing group vs 3.3% in the lowest dosing group; P < 0.01) or impairment of renal function (creatinine increase of 2 mg/dL postoperatively, 6.4% in the highest dosing group vs 10.0% in the lowest dosing group; P < 0.01) was lower with higher doses of aprotinin. Thus, there was no association between aprotinin dose and renal function. Our results support the hypothesis that a more individualized aprotinin regimen with potentially higher doses may optimize the effectiveness of aprotinin therapy in cardiac surgery.

This article has been cited by other articles:

				D. L. Ngaage, A. R. Cale, M. E. Cowen, S. Griffin, and L. Guvendik Aprotinin in Primary Cardiac Surgery: Operative Outcome of Propensity Score-Matched Study Ann. Thorac. Surg., October 1, 2008; 86(4): 1195 - 1202. [Abstract] [Full Text] [PDF]

				M. C. Grant, Z. Kon, A. Joshi, E. Christenson, S. Kallam, N. Burris, J. Gu, and R. S. Poston Is Aprotinin Safe to Use in a Cohort at Increased Risk for Thrombotic Events: Results From a Randomized, Prospective Trial in Off-Pump Coronary Artery Bypass Ann. Thorac. Surg., September 1, 2008; 86(3): 815 - 822. [Abstract] [Full Text] [PDF]

				A. D. Shaw, M. Stafford-Smith, W. D. White, B. Phillips-Bute, M. Swaminathan, C. Milano, I. J. Welsby, S. Aronson, J. P. Mathew, E. D. Peterson, et al. The Effect of Aprotinin on Outcome after Coronary-Artery Bypass Grafting N. Engl. J. Med., February 21, 2008; 358(8): 784 - 793. [Abstract] [Full Text] [PDF]

				P. J. Van der Linden, J.-F. Hardy, A. Daper, A. Trenchant, and S. G. De Hert Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome? Br. J. Anaesth., November 1, 2007; 99(5): 646 - 652. [Abstract] [Full Text] [PDF]

				W. Dietrich, A. Ebell, R. Busley, and A.-L. Boulesteix Aprotinin and Anaphylaxis: Analysis of 12,403 Exposures to Aprotinin in Cardiac Surgery Ann. Thorac. Surg., October 1, 2007; 84(4): 1144 - 1150. [Abstract] [Full Text] [PDF]

				M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action Anesth. Analg., October 1, 2007; 105(4): 949 - 962. [Abstract] [Full Text] [PDF]

				M. Buerke, D. Pruefer, D. Sankat, J. M. Carter, U. Buerke, M. Russ, A. Schlitt, I. Friedrich, J. Borgermann, C. F. Vahl, et al. Effects of Aprotinin on Gene Expression and Protein Synthesis After Ischemia and Reperfusion in Rats Circulation, September 11, 2007; 116(11_suppl): I-121 - I-126. [Abstract] [Full Text] [PDF]

				C. W. Hogue and M. J. London Aprotinin Use During Cardiac Surgery: A New or Continuing Controversy? Anesth. Analg., November 1, 2006; 103(5): 1067 - 1070. [Full Text] [PDF]